ResultsIQ

ResultsIQ › Latest results › Biocon Limited

Biocon Limited Q1 FY27 results deck summary

NSE: BIOCON · BSE: 532523

Results deck of 6 Aug 2026, summarised by AI from the filing.

Q1 FY27 revenue from operations ₹4,336 cr, up 10% YoY, with Biosimilars growth led by North America and H2 expected to be meaningfully better.

Key takeaways

  1. Q1 revenue Revenue from operations ₹4,336 cr (Q1 FY26: ₹3,942 cr, +10% YoY); reported net profit ₹141 cr (Q1 FY26: ₹31 cr, +355%).
  2. Generics margin Generics EBITDA margin up over 250bps QoQ to 7%, from 5% in Q4 FY26.
  3. Growth driver Biosimilars growth led primarily by North America; generic liraglutide a key driver across multiple markets including the USA.

Original filing on BSE

Biocon Limited Q1 FY27 results

As filed: Revenue ₹4,336 cr (+10% year on year), EBITDA ₹847 cr (+13% year on year), PAT ₹137 cr (+45% year on year), EBITDA margin 19.5% (+54 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹4,517 cr (+2% year on year), EBITDA ₹1,020 cr (−5% year on year), PAT ₹199 cr (−30% year on year), EBITDA margin 22.6% (−182 bps). Score 32 of 100, Below trend. Revenue, EBITDA and profit before exceptional items growth were below the company's own trend. EBITDA margin fell 182 bps year on year. Consolidated profit -57% but standalone +143%. Share price after the results: +7.9% in 29 days (Nifty 500: −3.2%).
  • Q3 FY26: Revenue ₹4,173 cr (+9% year on year), EBITDA ₹834 cr (+11% year on year), PAT −₹51.8 cr (+63% year on year), EBITDA margin 20.0% (+32 bps). Score 53 of 100, In line with trend. Revenue, EBITDA and profit before exceptional items growth were in line with the company's own trend. EBITDA margin rose 32 bps year on year. Share price after the results: +2.3% in 29 days (Nifty 500: −9.6%).
  • Q2 FY26: Revenue ₹4,296 cr (+20% year on year), EBITDA ₹835 cr (+22% year on year), PAT ₹133 cr (+300% year on year), EBITDA margin 19.4% (+36 bps). Score 64 of 100, In line with trend. Revenue and EBITDA growth were above the company's own trend; profit growth was well above it. EBITDA margin rose 36 bps year on year. Other income 54% of PBT. Share price after the results: −0.9% in 30 days (Nifty 500: −0.6%).
  • Q1 FY26: Revenue ₹3,942 cr (+15% year on year), EBITDA ₹749 cr (+21% year on year), PAT ₹89.0 cr (−90% year on year), EBITDA margin 19.0% (+94 bps). Score 46 of 100, In line with trend. Revenue and EBITDA growth were above the company's own trend; profit growth was below it. EBITDA margin rose 94 bps year on year. Other income 82% of PBT. Tax rate 8%. Revenue fell 11% from last quarter. Share price after the results: −0.1% in 29 days (Nifty 500: +0.6%).
  • Q4 FY25: Revenue ₹4,417 cr (+13% year on year), EBITDA ₹1,078 cr (+18% year on year), PAT ₹459 cr (+106% year on year), EBITDA margin 24.4% (+102 bps). Score 61 of 100, In line with trend. Revenue, EBITDA and profit growth were above the company's own trend. EBITDA margin rose 102 bps year on year. Tax rate 6%. Share price after the results: −1.4% in 29 days (Nifty 500: +6.1%).
  • Q3 FY25: Revenue ₹3,821 cr (−3% year on year), EBITDA ₹751 cr (−19% year on year), PAT ₹81.0 cr (−83% year on year), EBITDA margin 19.7% (−379 bps). Score 20 of 100, Below trend. Revenue, EBITDA and profit before exceptional items growth were below the company's own trend. EBITDA margin fell 379 bps year on year. Tax rate 48%. Consolidated profit -89% but standalone +2333%.
  • Q2 FY25: Revenue ₹3,590 cr (+4% year on year), EBITDA ₹685 cr (−8% year on year), PAT ₹27.0 cr (−73% year on year), EBITDA margin 19.1% (−235 bps). Score 8 of 100, Below trend. EBITDA margin fell 235 bps year on year. Other income 34% of PBT. Tax rate 72%. Not enough history for a trend yet: scored on growth alone. Profit fell 94% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Biocon Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.